News

Rob Quinn To Join BenevolentAI As Chief Financial Officer in January 2021

BenevolentAI was founded with the belief that innovative thinking united with purposeful technology can lead to innovation that will fundamentally change patients’ lives for the better.  As we scale our bold and audacious mission, we require equally specialist expertise to guide our growth and financial direction.

To help us meet this need, we are thrilled to be welcoming Rob Quinn to the BenevolentAI team as our new Chief Finance Officer from January 2021.  He will take overall responsibility for the Finance Organisation, with a focus on investor relations, fundraising, revenue opportunities and realising our long term growth plans.

Rob brings with him a wealth of scientific and financial experience, having served at GSK as Area Finance Director for Africa & Developing Countries, and as CFO of Silence Therapeutics plc, where he led their listing on Nasdaq. He obtained a PhD in Biochemistry from the University of Manchester and qualified as a Chartered Accountant at Deloitte, where he spent time working in corporate finance advisory within the life sciences sector.

"I am excited to be joining BenevolentAI as Chief Financial Officer” Rob commented, “Benevolent is a business with huge potential and big ambitions to transform the lives of patients, and I look forward to playing my part". 

Under Rob’s financial guidance, we will confidently continue to move towards greater levels of innovation by investing in building richer and better technology that will help uncover vital new treatments. 


More Posts

You Might Also Like

Blog
Intern at BenevolentAI part I: meet our 2020 intern cohort
What impactful work did our interns get up to across Engineering, Data Science, ML and business operations this summer? Get to know them and their work in our tech internships blog.
Nov 26, 2020
News
FDA grants Emergency Use Authorisation for baricitinib in hospitalised COVID-19 patients nine months after initial hypothesis was published by BenevolentAI
BenevolentAI scientists first identified baricitinib as a potential treatment for COVID-19 in early February 2020 using Benevolent's AI tools and biomedical knowledge graph.
Nov 20, 2020
News
BenevolentAI at NeurIPS 2020: Machine Learning in Drug Discovery
BenevolentAI is happy to announce it is sponsoring NeurIPS 2020. Join us to hear about data diversity and ML applied drug discovery, and to learn about careers in the field.
Nov 17, 2020
Blog
Careers with Impact: 5 learnings from machine learning applied drug discovery
Last week, we brought together four of our exceptional colleagues for a panel discussion on careers in machine learning applied drug discovery. Here are some of our main takeaways:
Nov 17, 2020
Blog
Data published in Science Advances shows baricitinib reduces COVID-19 morbidity and mortality
Research published in Science Advances supports BenevolentAI’s AI-generated hypothesis from late January for baricitinib as a treatment for COVID-19.
Nov 13, 2020
News
Sir Nigel Shadbolt joins BenevolentAI as a non-executive director
BenevolentAI strengthens its Board with the appointment of AI pioneer Sir Nigel Shadbolt as Non-Executive Director.
Nov 3, 2020